Bookmark this page – or download the information directly, if you prefer – to ensure you’re always connected to the latest and greatest information on the very best in NSCLC treatment regimens (NCCN Guidelines).
Publication: JAMA Oncology Objective: With NSCLC having relatively poor outcomes and the significant data supporting the use of metformin as an antineoplastic agent, the researchers wanted to compare overall or progression-free survival in chemoradiation alone vs. chemoradiation + metformin stage III NSCLC patients. Design: Randomized clinical trial, open-label, phase 2 study; 167 eligible patients
In this JAMA Original Investigation, the researchers studied 19,529 patients with Medicare coverage who initiated first systemic therapy for advanced non–small cell lung cancer (NSCLC) using 1 of 4 regimens of checkpoint inhibitor immunotherapy, cytotoxic chemotherapy, and combined chemoimmunotherapy. The goal? To gauge the uptake and effectiveness of immunotherapy among older patients outside clinical trials.
Although the MYSTIC phase 3 clinical trial examining durvalumab therapy for non–small-cell lung cancer (NSCLC) did not meet its primary end points – overall survival (OS) and progression-free survival (PFS) – it did show a numerically reduced risk for death with durvalumab (Imfinzi) versus chemotherapy in patients with PD-L1 expression on ≥25% of tumor cells.
Dr. David P. Carbone, Director of the Thoracic Oncology Center at Ohio State University, comments on a study evaluating the efficacy of anti–PD1/PD-L1 monotherapy for patients with NSCLC and active brain metastases: “…the initial hope that PD‑1 inhibitors could be active on brain metastases has not been fully fulfilled, and the aggressive use of stereotactic […]
In addition to reducing pack-years history of smoking, the recommendation calls for annual screening for lung cancer at age 50 years instead of age 55 years, an update of the U.S. Preventive Services Task Force (USPSTF) guidance on lung cancer screening issued 7 years ago.
The Journal of Clinical Oncology published the double-blind, phase 3 KEYNOTE-604 clinical trial study results, which sought to compare pembrolizumab plus etoposide and platinum (EP) with placebo plus EP in treatment-naïve patients with ES-SCLC.
The findings, recently published in the Journal of Thoracic Oncology, suggested that patients with ALK rearrangements may benefit from prophylactic anticoagulation, and venous thromboembolism risk prediction scores may improve if ALK rearrangement status is incorporated.
The approval of capmatinib and its companion diagnostic is the first of its kind for this specific diagnosis, using next-generation sequencing to perform comprehensive genomic profiling of solid tumors. It now has FDA approval for 21 different agents.
According to the results of a single-arm, multicenter phase 2 trial in JAMA Oncology, low-dose erlotinib may be a safe and effective option for frail or elderly patients with EGFR mutation-positive NSCLC.